Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Matinas BioPharma stock

Own Matinas BioPharma stock in just a few minutes.

Matinas BioPharma Holdings, Inc is a biotechnology business based in the US. Matinas BioPharma shares (MTNB) are listed on the NYSE MKT and all prices are listed in US Dollars. Matinas BioPharma employs 20 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Matinas BioPharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MTNB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Matinas BioPharma share price

Use our graph to track the performance of MTNB stocks over time.

Matinas BioPharma shares at a glance

Information last updated 2021-04-23.
52-week range$0.66 - $2.22
50-day moving average $1.07
200-day moving average $1.12
Wall St. target price$3.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.13

Buy Matinas BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Matinas BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Matinas BioPharma financials

Revenue TTM $158,333
Gross profit TTM $-14,200,585
Return on assets TTM -27.21%
Return on equity TTM -46.39%
Profit margin 0%
Book value $0.30
Market capitalisation $179.8 million

TTM: trailing 12 months

Shorting Matinas BioPharma shares

There are currently 15.8 million Matinas BioPharma shares held short by investors – that's known as Matinas BioPharma's "short interest". This figure is 2% up from 15.5 million last month.

There are a few different ways that this level of interest in shorting Matinas BioPharma shares can be evaluated.

Matinas BioPharma's "short interest ratio" (SIR)

Matinas BioPharma's "short interest ratio" (SIR) is the quantity of Matinas BioPharma shares currently shorted divided by the average quantity of Matinas BioPharma shares traded daily (recently around 1.9 million). Matinas BioPharma's SIR currently stands at 8.51. In other words for every 100,000 Matinas BioPharma shares traded daily on the market, roughly 8510 shares are currently held short.

However Matinas BioPharma's short interest can also be evaluated against the total number of Matinas BioPharma shares, or, against the total number of tradable Matinas BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Matinas BioPharma's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Matinas BioPharma shares in existence, roughly 80 shares are currently held short) or 0.0806% of the tradable shares (for every 100,000 tradable Matinas BioPharma shares, roughly 81 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Matinas BioPharma.

Find out more about how you can short Matinas BioPharma stock.

Matinas BioPharma share dividends

We're not expecting Matinas BioPharma to pay a dividend over the next 12 months.

Matinas BioPharma share price volatility

Over the last 12 months, Matinas BioPharma's shares have ranged in value from as little as $0.66 up to $2.22. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Matinas BioPharma's is 2.6404. This would suggest that Matinas BioPharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Matinas BioPharma overview

Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Frequently asked questions

What percentage of Matinas BioPharma is owned by insiders or institutions?
Currently 3.814% of Matinas BioPharma shares are held by insiders and 21.405% by institutions.
How many people work for Matinas BioPharma?
Latest data suggests 20 work at Matinas BioPharma.
When does the fiscal year end for Matinas BioPharma?
Matinas BioPharma's fiscal year ends in December.
Where is Matinas BioPharma based?
Matinas BioPharma's address is: 1545 Route 206 South, Bedminster, NJ, United States, 07921
What is Matinas BioPharma's ISIN number?
Matinas BioPharma's international securities identification number is: US5768101058
What is Matinas BioPharma's CUSIP number?
Matinas BioPharma's Committee on Uniform Securities Identification Procedures number is: 576810105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site